Novo Nordisk (NYSE: NVO) reported Q3 EPS of DKK4.50. Revenue for the quarter came in at DKK74.98 billion.

OUTLOOK

For the full-year 2025 outlook, sales growth is now expected to be 8-11% at CER with operating profit growth now
expected to be 4-7% also at CER, including a negative full-year impact of around DKK 8 billion from the company-wide
transformation. Sales and operating profit growth reported in Danish kroner is now expected to be 4 and 6 percentage
points lower than at CER, respectively. The narrowing of the guidance ranges reflects lowered growth expectations for
Novo Nordisk's GLP-1 treatments within diabetes and obesity.

For earnings history and earnings-related data on Novo Nordisk (NVO) click here.